Cytogenetic Abnormalities and Treatment with New Drugs on Clinical Trials Are Important Prognostic Markers for Myeloma in the Era of ISS and FISH Analysis
- Resource Type
- Abstract
- Source
- In
Blood 2 December 2016 128(22):4498-4498 - Subject
- Language
- ISSN
- 0006-4971